Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Analyzing ISRG's Recent Stock Decline

This afternoon we watched Intuitive Surgical drop -3.9% to a price of $449.24 per share. The Large-Cap Specialty Industrial Machinery company is now trading -22.83% below its average target price of $582.1. Analysts have set target prices ranging from $350.0 to $685.0 per share for Intuitive Surgical, and have given the stock an average rating of buy.

The stock has a very low short interest at 1.4%, and a short ratio of 2.35. The company's insiders own 0.53% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 89.0% of Intuitive Surgical's shares being owned by this investor type.

Institutions Invested in Intuitive Surgical

Date Reported Holder Percentage Shares Value
2025-06-30 Vanguard Group Inc 9% 33,335,833 $14,975,622,449
2025-06-30 Blackrock Inc. 9% 31,516,587 $14,158,353,499
2025-06-30 State Street Corporation 4% 15,552,203 $6,986,593,686
2025-06-30 Price (T.Rowe) Associates Inc 4% 13,415,471 $6,026,698,918
2025-06-30 FMR, LLC 2% 8,659,892 $3,890,326,455
2025-06-30 Geode Capital Management, LLC 2% 8,188,685 $3,678,643,786
2025-06-30 JPMORGAN CHASE & CO 2% 7,675,679 $3,448,183,543
2025-06-30 Capital World Investors 2% 7,612,458 $3,419,782,458
2025-06-30 Morgan Stanley 2% 6,104,299 $2,742,264,671
2025-06-30 NORGES BANK 1% 4,728,033 $2,123,997,835

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Intuitive Surgical.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS